OYSTER POINT PHARMACEUTICALS

oyster-point-pharmaceuticals-logo

Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. Dry eye disease is a chronic, progressive condition that impacts more than 30 million Americans and is growing in prevalence. OC-01’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the Lacrimal Functional Unit (LFU).

#SimilarOrganizations #People #Financial #Website #More

OYSTER POINT PHARMACEUTICALS

Industry:
Biopharma Clinical Trials Health Care Medical Pharmaceutical

Founded:
2015-01-01

Address:
San Francisco, California, United States

Country:
United States

Website Url:
http://www.oysterpointrx.com

Total Employee:
11+

Status:
Active

Email Addresses:
[email protected]

Total Funding:
235.8 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Wordpress Plugins


Similar Organizations

edgewise-therapeutics-logo

Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.


Current Advisors List

jeffrey-nau_image

Jeffrey Nau Board Member @ Oyster Point Pharmaceuticals
Board_member

clare-ozawa_image

Clare Ozawa Board Member @ Oyster Point Pharmaceuticals
Board_member

ali-behbahani_image

Ali Behbahani Board Member @ Oyster Point Pharmaceuticals
Board_member

mark-murray_image

Mark Murray Board Member @ Oyster Point Pharmaceuticals
Board_member

william-j-link_image

William J. Link Board Member @ Oyster Point Pharmaceuticals
Board_member

michael-ackermann_image

Michael Ackermann Board Chairman @ Oyster Point Pharmaceuticals
Board_member
2017-10-01

Current Employees Featured

not_available_image

Donald J. Santel
Donald J. Santel Non-executive Chairperson, Director @ Oyster Point Pharmaceuticals
Non-executive Chairperson, Director
2021-07-01

michael-ackermann_image

Michael Ackermann
Michael Ackermann Chairman @ Oyster Point Pharmaceuticals
Chairman
2017-10-01

loni-da-silva_image

Loni da Silva
Loni da Silva Senior Vice President, Regulatory Affairs @ Oyster Point Pharmaceuticals
Senior Vice President, Regulatory Affairs

mark-murray_image

Mark Murray
Mark Murray CFO @ Oyster Point Pharmaceuticals
CFO

jeffrey-nau_image

Jeffrey Nau
Jeffrey Nau CEO @ Oyster Point Pharmaceuticals
CEO
2017-03-01

patricia-johnson_image

Patricia Johnson
Patricia Johnson Executive Director, Regulatory CMC @ Oyster Point Pharmaceuticals
Executive Director, Regulatory CMC
2018-04-01

john-snisarenko_image

JOHN SNISARENKO
JOHN SNISARENKO Chief Commercial Officer @ Oyster Point Pharmaceuticals
Chief Commercial Officer

puja-shah_image

Puja Shah
Puja Shah Medical Director @ Oyster Point Pharmaceuticals
Medical Director
2020-12-01

daniel-lochner_image

DANIEL LOCHNER
DANIEL LOCHNER Chief Financial Officer @ Oyster Point Pharmaceuticals
Chief Financial Officer

Founder


jeffrey-nau_image

Jeffrey Nau

mark-murray_image

Mark Murray

Stock Details


Company's stock symbol is NASDAQ:OYST

Investors List

flying-l-partners_image

Flying L Partners

Flying L Partners investment in Series B - Oyster Point Pharmaceuticals

vida-ventures_image

Vida Ventures

Vida Ventures investment in Series B - Oyster Point Pharmaceuticals

new-enterprise-associates_image

New Enterprise Associates

New Enterprise Associates investment in Series B - Oyster Point Pharmaceuticals

invus_image

Invus

Invus investment in Series B - Oyster Point Pharmaceuticals

versant-ventures_image

Versant Ventures

Versant Ventures investment in Series B - Oyster Point Pharmaceuticals

new-enterprise-associates_image

New Enterprise Associates

New Enterprise Associates investment in Series A - Oyster Point Pharmaceuticals

versant-ventures_image

Versant Ventures

Versant Ventures investment in Series A - Oyster Point Pharmaceuticals

Official Site Inspections

http://www.oysterpointrx.com Semrush global rank: 3.82 M Semrush visits lastest month: 3.47 K

  • Host name: edge.redirect.pizza
  • IP address: 89.106.200.1
  • Location: Luxembourg
  • Latitude: 49.7498
  • Longitude: 6.1661
  • Timezone: Europe/Luxembourg

Loading ...

More informations about "Oyster Point Pharmaceuticals"

Oyster Point Pharmaceuticals - Crunchbase

Oyster Point Pharmaceuticals may be growing as indicated by the expansion of its headquarters, which has tripled in size, suggesting an increase in operational capacity. This physical expansion is a strong indicator of growth, reflecting a …See details»

Oyster Point Pharma - LinkedIn

Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.See details»

Oyster Point Pharma Information - RocketReach

Oyster Point Pharma is a Pharmaceutical Manufacturing, Drug Manufacturing & Research, and Biopharma company located in Princeton, New Jersey with $27.2 million in revenue and 164 …See details»

Oyster Point Pharma - businessabc.net

Nov 18, 2024 Oyster Point was founded in 2014 by two industry veterans with decades of experience in the biopharmaceutical space. Oyster Point has since grown to become a leader …See details»

Oyster Point Company Profile 2024: Valuation, …

Information on acquisition, funding, investors, and executives for Oyster Point. Use the PitchBook Platform to explore the full profile.See details»

Oyster Point Pharma Staff Directory & Email Format - ContactOut

Explore Oyster Point Pharma staff directory for direct access to contact details on 278 employees including email format, email address and phone numbers.See details»

Oyster Point Pharma - ZoomInfo

View Oyster Point Pharma (www.oysterpointrx.com) location in New Jersey, United States , revenue, industry and description. Find related and similar companies as well as employees …See details»

About OYSTER POINT PHARMA, INC. | DxMultiomics

OYSTER POINT PHARMA, INC. | on DxMultiomics. Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of …See details»

Working at Oyster Point Pharma - Zippia

Find out what it's like to work at Oyster Point Pharma. See what kind of people work at Oyster Point Pharma, career paths working at Oyster Point Pharma, company culture, salaries, …See details»

Barry Rosenfield - Oyster Point Pharma

You are now leaving OysterPointRx.com. Would you like to continue?See details»

Oyster Point Pharma Expands Executive Leadership Team

Sep 19, 2019 Oyster Point Pharma, Inc., today announced the appointment of Dan Lochner, MBA as its Chief Financial Officer and John Snisarenko, MBA as Chief Commercial Officer. …See details»

Oyster Point Pharma Announces TYRVAYA® To Be Covered By the

Aug 17, 2022 Copies of these filings are available online at www.oysterpointrx.com. Any forward-looking statement made in this press release speaks only as of the date of this release.See details»

Oyster Point Pharma, a Leading Ophthalmology-Focused …

Nov 7, 2022 Tender Offer to Acquire All Outstanding Shares of Oyster Point Pharma for $11.00 per Share, Plus a Contingent Value Right of Up To $2.00 per Share PRINCETON, N.J., Nov. …See details»

Oyster Point Pharma Announces TYRVAYA® To Be Covered By the …

Aug 17, 2022 Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical …See details»

Oyster Point Pharma Reports Fourth Quarter and Full Year 2021 …

PRINCETON, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical …See details»

Oyster Point Pharma Announces Expanded Patient Access to …

Jul 27, 2022 TYRVAYA Now Covered by Commercial Prescription Drug Plans Managed by the Nation’s Top Three Pharmacy Benefit Manager (PBM) Group Purchasing Organizations …See details»

Oyster Point Pharma Reports First Quarter 2022 Financial Results …

May 5, 2022 “We are very pleased with the performance of Oyster Point Pharma’s first full quarter since the launch of TYRVAYA®.” said Jeffrey Nau, Ph.D., MMS, president and chief …See details»

Recommended Stories - Yahoo Finance

PRINCETON, N.J., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, …See details»

Oyster Point Pharma Announces TYRVAYA™ Nasal Spray Now …

Feb 22, 2022 One of the largest pharmacy benefit management (PBM) companies in the United States has added TYRVAYA (varenicline solution) Nasal Spray to National Preferred, Basic …See details»

linkstock.net © 2022. All rights reserved